Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

@article{Papadopoulos2015UnexpectedHI,
  title={Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor},
  author={Kyriakos P. Papadopoulos and Randi Isaacs and Sanela Bilic and Kerstin Kentsch and Heather A. Huet and Matthias Hofmann and Drew R Rasco and Nicole Kundamal and Zhongwhen Tang and Jennifer F. Cooksey and Amit Mahipal},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2015},
  volume={75},
  pages={887-895}
}
TAS266 is a novel agonistic tetravalent Nanobody® targeting the DR5 receptor. In preclinical studies, TAS266 was more potent than a cross-linked DR5 antibody or TRAIL. This first-in-human study was designed to evaluate the safety and tolerability, maximum tolerated dose, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of TAS266. Adult patients with advanced solid tumors were to receive assigned doses of TAS266 (3, 10, 15, or 20 mg/kg) intravenously on days 1, 8, 15… CONTINUE READING